ktx-2001
(2)
K36 Therapeutics, Inc.
K36 Therapeutics is a Cambridge, Massachusetts clinical-stage biotech developing first-in-class oral small-molecule inhibitors of NSD2/MMSET, an epigenetic enzyme that drives hard-to-treat cancers. Its lead candidate, gintemetostat (KTX-1001), is in Phase 1 for relapsed/refractory multiple myeloma carrying the t(4;14) translocation, and a second program, KTX-2001, targets metastatic castration-resistant prostate cancer. Backed by Atlas Venture, F-Prime Capital, Eight Roads Ventures, Nextech Invest and Bristol Myers Squibb, K36 has raised roughly $100M+ to translate chromatin biology into precision cancer medicines.
Terrence Connolly
Terrence (Terry) Connolly is a chemist-turned-dealmaker who runs K36 Therapeutics, a Cambridge, Massachusetts biotech chasing a single target: NSD2/MMSET, an epigenetic switch that drives hard-to-treat cancers. A Ph.D. organic chemist who started at the lab bench making molecules at Roche, Wyeth and Celgene, he crossed over into business development at Celgene, closed more than two dozen deals, then ran the business side at Skyhawk and Dragonfly. In 2021 he took the top job at K36, and now steers its lead compounds KTX-1001 (for t(4;14) multiple myeloma) and KTX-2001 (for treatment-resistant prostate cancer) through early clinical trials, backed by a $70 million Series B led by Nextech Invest with Bristol Myers Squibb participating.